Which tumor marker is most sensitive and specific for monitoring treatment response and recurrence in epithelial ovarian cancer?

Explanation

## Tumor Markers in Epithelial Ovarian Cancer **Key Point:** CA-125 (cancer antigen 125) is the most widely used and clinically relevant tumor marker for epithelial ovarian cancer. It is elevated in 80–90% of advanced-stage disease and 50% of early-stage disease. ### Comparison of Tumor Markers in Ovarian Cancer | Marker | Sensitivity (Advanced) | Specificity | Clinical Use | Limitations | | --- | --- | --- | --- | --- | | CA-125 | 80–90% | 95% (in OC context) | Diagnosis, monitoring, recurrence | Elevated in benign conditions (endometriosis, menstruation, fibroids) | | AFP | <5% | High | Germ cell tumors, yolk sac tumors | Not useful for epithelial OC | | hCG | <5% | High | Germ cell tumors, choriocarcinoma | Not useful for epithelial OC | | CEA | 10–20% | Low | Non-specific marker | Poor sensitivity and specificity for OC | **High-Yield:** CA-125 is used for: 1. **Initial diagnosis** — elevated in 80–90% of advanced epithelial ovarian cancer 2. **Monitoring treatment response** — decline in CA-125 correlates with chemotherapy efficacy 3. **Detecting recurrence** — rising CA-125 often precedes clinical or radiological evidence of recurrence by weeks to months 4. **Prognostic stratification** — baseline CA-125 level correlates with stage and survival **Warning:** CA-125 is NOT specific to ovarian cancer. Benign conditions that elevate CA-125 include: - Endometriosis - Menstruation - Uterine fibroids - Pelvic inflammatory disease - Cirrhosis and ascites - Malignancies of breast, pancreas, lung, and colon **Clinical Pearl:** In the context of suspected ovarian cancer, a CA-125 level >35 U/mL combined with imaging findings (pelvic mass, ascites) significantly increases the probability of malignancy. However, CA-125 alone cannot diagnose ovarian cancer; it must be interpreted alongside clinical and radiological findings. **Mnemonic:** **CA-125 for OC** — CA-125 is the gold standard marker for Ovarian Cancer monitoring and recurrence detection. ### Why AFP and hCG Are Wrong in This Context AFP and hCG are elevated in **germ cell tumors** (yolk sac tumor, choriocarcinoma, dysgerminoma) and **non-epithelial ovarian malignancies**, not in epithelial ovarian cancer. They are not useful for monitoring epithelial ovarian cancer. [cite:Williams Gynecology 3e Ch 32]